Hyperkalemia Clinical Trial
Official title:
IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors
There are limited data regarding the burden of hyperkalaemia in patients attending emergency departments (ED) or who are hospitalised (excluding those already receiving dialysis). Renin-angiotensin-aldosterone system inhibitors (RAASi) are of prognostic benefit in patients with heart failure with reduced ejection fraction (HFrEF) and post myocardial infarction (MI) left ventricular systolic dysfunction (LVSD) and as such should be continued wherever possible for these indications. These drugs may contribute to elevation in serum potassium and hyperkalaemia may lead to a reduction in dose or complete withdrawal of RAASi. Yet it remains unknown how common this happens in standard clinical practice. Inappropriate discontinuation of RAASi in such patients may lead to adverse clinical outcomes. If patients have hyperkalaemia that limits the use of RAASi, they may be candidates for new potassium binders that could facilitate their continued use.
Research questions: In an adult population of patients who are hospitalised or attending the emergency department (and not receiving dialysis) with hyperkalaemia: 1. How does hyperkalaemia impact on RAASi therapy and does this vary according to the clinical indication for the drug(s)? 2. What are the demographics, co-morbidities and drug history for patients presenting with hyperkalaemia? 3. What is the frequency of subsequent hospitalisations and mortality rate in a cohort of patients presenting with hyperkalaemia at 12 months? ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03172702 -
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
|
Phase 3 | |
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Recruiting |
NCT05766839 -
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
|
Phase 2 | |
| Completed |
NCT02609841 -
POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
|
N/A | |
| Recruiting |
NCT06277128 -
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
|
Phase 2 | |
| Recruiting |
NCT04789239 -
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
|
Phase 2 | |
| Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT04443608 -
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
|
Phase 4 | |
| Completed |
NCT02607085 -
REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study
|
N/A | |
| Completed |
NCT03283267 -
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
|
Phase 1 | |
| Recruiting |
NCT06036823 -
5 Versus 10 Units of Insulin in Hyperkalemia Management
|
Phase 4 | |
| Recruiting |
NCT05173584 -
Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.
|
Phase 4 | |
| Completed |
NCT05184998 -
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
|
||
| Completed |
NCT01737697 -
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
|
Phase 3 | |
| Completed |
NCT01493024 -
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
|
Phase 2 | |
| Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
| Completed |
NCT05382988 -
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
|
Phase 3 | |
| Completed |
NCT04217590 -
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
|
Phase 3 | |
| Recruiting |
NCT03096561 -
Measurement of Serum Potassium Rate During Accidental Hypothermia.
|
N/A | |
| Completed |
NCT03326583 -
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
|
Phase 2 |